Substance / Medication

Vorinostat

Overview

Active Ingredient

vorinostat

RxNorm CUI

194337

Indications

® ZOLINZAis indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.

Labeler: Merck Sharp & Dohme LLCUpdated: 2024-11-12T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Primary cutaneous T-cell lymphoma

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.

Garcia-Manero Guillermo, Podoltsev Nikolai A, Othus Megan et al. · Leukemia · 2024

PMID: 37935977RCTFull text (PMC)

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.

Jenner Matthew W, Pawlyn Charlotte, Davies Faith E et al. · Br J Haematol · 2023

PMID: 36541152RCTFull text (PMC)

Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.

Scully Eileen P, Aga Evgenia, Tsibris Athe et al. · Clin Infect Dis · 2022

PMID: 35176755RCTFull text (PMC)

Effect of Decitabine (5-aza-2'-deoxycytidine, 5-aza-CdR) in Comparison with Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) on DNMT1, DNMT3a and DNMT3b, HDAC 1-3, SOCS 1, SOCS 3, JAK2, and STAT3 Gene Expression in Hepatocellular Carcinoma HLE and LCL-PI 11 Cell Lines.

Sanaei Masumeh, Kavoosi Fraidoon, Pourahmadi Mohammad · Asian Pac J Cancer Prev · 2021

PMID: 34319031ObservationalFull text (PMC)

Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy.

Zierfuss Bettina, Weinhofer Isabelle, Kühl Jörn-Sven et al. · Ann Clin Transl Neurol · 2020

PMID: 32359032ObservationalFull text (PMC)

Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.

Miles Mark A, Harris Michael A, Hawkins Christine J · Apoptosis · 2019

PMID: 30997620Observational

Validation of an LC-MS/MS method for simultaneous detection of four HDAC inhibitors - belinostat, panobinostat, rocilinostat and vorinostat in mouse plasma and its application to a mouse pharmacokinetic study.

Giri Kalpesh Kumar, Suresh P S, Saim Syed Mohd et al. · Biomed Chromatogr · 2017

PMID: 27925271Observational

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.

Mota Talia M, Rasmussen Thomas A, Rhodes Ajantha et al. · AIDS · 2017

PMID: 28301423ObservationalFull text (PMC)

Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood.

Liu Lu, Detering Jan-Christoph, Milde Till et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2014

PMID: 24636840Observational

A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.

Yu Chia-Chun, Pan Shiow-Lin, Chao Shi-Wei et al. · Biochem Pharmacol · 2014

PMID: 24915421Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Vorinostat (substance)
SNOMED CT: 422505001
UMLS CUI: C0672708
RxNorm CUI: 194337
Labeler: Merck Sharp & Dohme LLC

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.